News | Radiopharmaceuticals and Tracers | August 30, 2017

ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes

Strategic partnership will support production and processing of radioisotopes on GE’s PETtrace 800 medical cyclotron platform

ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes

August 30, 2017 — ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation System (QIS) for radioisotope production. The goal of the partnership is to supply equipment, technologies and research that supports the production and processing of radioisotopes on GE’s PETtrace 800 platform of medical cyclotrons. The QIS integrates on to the GE PETtrace 800 series cyclotron to enable an alternative, non-reactor supply of valuable medical isotopes including technetium-99m, copper-64, gallium-68 and zirconium-89.

The strategic partnership includes an agreement for ARTMS to supply and install Europe’s first QUANTM system and research into expanding the number of available isotopes produced on GE’s PETtrace 800 series medical cyclotrons. ARTMS will work with GE to optimize the production and processing of isotopes such as copper-64 and gallium-68.

Every year Tc-99m is used in over 80 percent of all nuclear medicine imaging procedures in areas such as cardiology, oncology and neurology. Recently, Tc-99m produced with the QUANTM system was used to complete a Canadian multi-centre registration trial in bone imaging and thyroid function.

In the future, it is the intent of ARTMS and GE to continue to offer the QUANTM system to new and existing PETtrace cyclotron customers on a global basis.

The QUANTM technology includes all the required products and procedures for the production of Tc-99m using GE’s PETtrace cyclotrons and enables the production of other valuable isotopes through the bombardment of a high-energy proton beam against specific chemical ‘targets’.

The ARTMS process provides a cost-effective alternative to reactor-based technology. The technology produces no long-lived radioactive waste and advances efforts to eliminate the use of weapons-grade highly enriched uranium (HEU) in radioisotope production around the world.

For more information: www.gehealthcare.com, www.artmsproducts.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...